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Studies have suggested that maternal polyunsaturated fatty acid (PUFA) status 
during pregnancy may influence early childhood allergic diseases, although 
findings are inconsistent. We examined the relation between maternal PUFA 
status and risk of allergic diseases in early childhood in an Asian study. 
Maternal plasma samples (n=998) from the GUSTO mother-offspring cohort 
were assayed at 26-28 weeks of gestation for relative abundance of PUFAs. 
Offspring were followed up from 3 weeks to 18 months of age, and clinical 
outcomes of potential allergic diseases (rhinitis, eczema, and wheezing) were 
assessed by repeated questionnaires. Skin prick testing (SPT) was also 
performed at age 18 months. An allergic disease was defined as having any one 
of the clinical outcomes plus a positive SPT. The prevalences of a positive SPT, 
rhinitis, eczema, wheezing and any allergic disease were 14.1% (103/728), 26.5% 
(214/808), 17.6% (147/833), 10.9% (94/859), and 9.4% (62/657) 
respectively.PUFAs of interest were first independently analyzed as continuous 
variables to test for linear associations with various allergic outcomesi.e. SPT, 
rhinitis, eczema, wheezing and any allergic disease with positive SPT in the 
offspring using multiple linear regression models. To test for a possible 
non-linear relationship and to examine dose-response, the PUFAs were next 
categorized into quartiles within the total cohort, and binary logistic regression 
models used for independent analyses of associations between individual 
maternal PUFAs and the various allergic outcomes.After adjustment for 
confounders, maternal total n-3, n-6 PUFA status and the n-6:n-3 PUFA ratio 
were not significantly associated with offspring rhinitis, eczema, wheezing, a 
positive SPT and having any allergic disease with positive SPT in the 
VI 
 
offspring (P> 0.01 for all). A weak trend of higher maternal n-3 PUFA being 
associated with higher risk of allergic diseases with positive SPT in offspring 
was observed. These findings do not support the hypothesis that the risk of early 
childhood allergic diseases is modified by variation in maternal n-3 and n-6 
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Chapter 1: Introduction and literature review 1 
1.1 Introduction 2 
Allergic diseases are one of the most common group of diseases worldwide, 3 
resulting in a significant social and economic burden(1). In most children, 4 
eczema is the earliest clinical manifestation of allergy, starting during the first 5 
few months of life. Increasing evidence shows that infants who develop 6 
allergy in early life have an altered immune response at birth(2, 3), suggesting 7 
that allergic diseases may originate in utero. Thus, it is now postulated that 8 
early life interventions during the antenatal period may confer protective 9 
effects on the immune system(4). 10 
 11 
Changes in modern lifestyle, including diet, have coincided with the escalating 12 
rates of allergic diseases(5, 6). Amongst dietary factors, patters of intake of 13 
polyunsaturated fatty acids (PUFAs)have received great interest. The 14 
pro-inflammatory properties of n-6 PUFAs and anti-inflammatory properties 15 
of n-3 PUFAs are well-established in both human and animal models(7-10). 16 
For example, the n-6 PUFA arachidonic acid (AA; 20:4n-6) produces 17 
eicosanoid mediators like prostaglandin (PG)E2, which promotes the 18 
production of IgE, and leukotriene (LT)B4, which promotes airway 19 
constriction(8). In contrast, the n-3 PUFAs eicosapentanoic acid (EPA; 20 
20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) act to counter the effects 21 
of AA(7). Consequently, increased intake of n-6 PUFAs and decreased 22 
exposure to n-3 PUFAs in the antenatal period have been hypothesized to 23 
increase the risk of offspring allergic diseases(11). 24 
 25 
Fish and fish oil are sources of EPA and DHA. Fish oil supplementation 26 
studies in pregnant women(12-14) and observational studies on fish intake 27 
during pregnancy(15, 16) have suggested protective effects on offspring 28 
allergy. However, studies reporting the relationship between maternal plasma 29 
PUFA status and childhood allergic diseases have yielded inconsistent results. 30 
The Southampton Women’s Survey (SWS) study found a weak protective 31 
effect of maternal EPA, DHA and total n-3 PUFAs against non-atopic 32 
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persistent/late wheezing in offspring aged 6 years(17). The KOALA Birth 33 
Cohort found AA and the ratio of n-6 to n-3 PUFAs to be protective against 34 
childhood eczema(18). No significant associations were found in the Avon 35 
Longitudinal Study of Parents and Children (ALSPAC) cohort(19) or in 36 
another small study(20). Thus, whether higher n-3 PUFA status during 37 
pregnancy would lower the risk of childhood allergic diseases remains unclear.  38 
 39 
In the previous publications(17-20), most allergic outcome measurements 40 
were performed in Caucasian children aged 4-7 years. No study has been done 41 
in an Asian population to investigate allergic diseases at a younger age. In this 42 
study, we investigated the relationship between maternal PUFA status and 43 
potential allergic diseases up to the age of 18 months in an Asian multi-ethnic 44 
birth cohort. 45 
 46 
1.2 Atopy and allergic disorders 47 
1.2.1 Definitions 48 
1.2.1.1 Atopy, allergy and allergic diseases 49 
The nomenclature proposed in the October 2003 report of theNomenclature 50 
Review Committee of the World Allergy Organization defined atopy as a 51 
“personal and/or familial tendency, usually in childhood or adolescence, to 52 
become sensitized and produce IgE antibodies in response to ordinary 53 
exposures to allergens, usually proteins”(21).As a consequence, atopy is a 54 
tendency for exaggerated IgE responses. The term atopycannot be used until an 55 
IgE sensitization has been documented by IgE antibodies in serum or by a 56 
positive skin prick test (SPT)(21). 57 
 58 
Allergy is defined as a “hypersensitivity reaction initiated by specific 59 
immunologic mechanisms”(21).Allergy refers to the clinical expression of 60 
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allergic diseases, including asthma, rhinitis, eczema and food allergy. 61 
 62 
Allergic diseases are manifest as hyper-responsiveness in the target organ, 63 
whether skin (eczema), nose (rhinitis), lung (asthma), or gastrointestinal tract 64 
(food allergy). (Figure 1-1) 65 
 66 
Figure 1-1Allergy and allergic diseases(22) 67 
 68 
What makes allergy complicated is that only a proportion of atopic subjects 69 
(with a positive SPT result) have clinical symptoms (asthma, rhinitis, eczema); 70 
and those with clinical symptoms may not have a positive SPT result.Clinical 71 
symptoms are classified as non-allergic when total IgE is normal and/or specific 72 
IgE to common allergens is not detected in the serum or on skin-prick test. For 73 
example, in a whole-population birth cohort, it was reported that 30% to 40% of 74 
cases of the clinical symptoms in 4 year old children are attributableto atopy and 75 
60% to 70% of cases could be accounted forby organ-based and other 76 
factors(23). 77 
 78 
In addition to systematic allergy (a positive skin prick test), recent researches 79 
are exploring the potential importance of local inflammation and IgEproduction 80 
4 
 
in the mucosal tissue of the end organs. It was reported that in persistent 81 
non-allergic rhinitis, some patients may have local inflammation, nasal IgE 82 
production, and a positive response to a nasal allergen provocation test despite 83 
no evidence of systemic atopy(24). Furthermore, local allergic rhinitis (LAR) as 84 
a condition involving a localized nasal allergic response in the absence of 85 
systemic atopy has been identified(25, 26).As a consequence, although a 86 
genetic tendency of atopy may underlie all the allergic diseases, there could also 87 
be organ specific predispositions for the allergic symptoms (i.e. lower airways 88 
for asthma, nose for rhinitis and skin for eczema). In this case, different allergic 89 
diseasesmay deserve separate consideration, which will be elaborated in the 90 
following chapters.  91 
 92 
1.2.1.2 Asthma and wheeze 93 
Asthma is one of the most common chronic diseases of childhood, and is 94 
defined as a chronic inflammatory disease of the lower airways, leading to 95 
symptoms of recurrent wheezing and cough(27).Asthma has infancy origins 96 
and longitudinal studies found that of those children with asthma at age 7 years, 97 
about 40% have started wheezing during the first two years of life(28). 98 
 99 
Wheezing is a high pitched, whistling sound that occur when smaller airways 100 
are narrowed by presence of bronchospasm, swelling of mucosal lining, 101 
excessive amounts of secretions, or inhaled foreign body. It is heard mostly on 102 
expiration as a result of critical airway obstruction(29).The Tucson Children’s 103 
Respiratory Study, a prospective birth cohort studies starting in 1980, proposed 104 
three different patterns of recurrent wheezing in pediatric patients(30): transient 105 
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early wheezing, non-allergic wheezing, and allergic wheezing (31). Transient 106 
infant wheezing is relatively benign and most children would stop wheezing 107 
after the age of 3 years. Non-allergic wheezing is mainly triggered by viral 108 
infection and tends to remit later in childhood. Allergic wheezing is linked to 109 
IgE-mediated sensitization. It includes early atopic wheezingand late atopic 110 
wheezing.Early atopic wheezingtakes the most part ofwhat we have called in 111 
the past ‘persistent wheezing’. Late atopic wheezingis what we called in the 112 
past‘late-onset wheezing’, and the patients only started wheezing at 6 years of 113 
life. 114 
 115 
1.2.1.3 Rhinitis 116 
Rhinitis is an inflammation of the upper airways that is characterized by 117 
symptoms of runny (rhinorrhea) and/or blocked nose and/or sneezing occurring 118 
for two or more consecutive days and lasting for more than an hour for most 119 
days (32, 33).Diary recording of symptoms and their circumstances over a 120 
2-week period may be helpful in borderline cases. Though not viewed as life 121 
threatening, rhinitis impairs quality of life, sleep, work (34) and school 122 
performance(35), and have the long-term risk ofincreasing the development of 123 
asthma (36). 124 
 125 
From an etiologic point of view, noninfectious rhinitis has been traditionally 126 
classified as allergic rhinitis (AR) and nonallergic rhinitis (NAR) based on the 127 
presence and absence of allergic sensitization(32).However, this approach has 128 
recently been suggestedto be incomplete because patients previously given a 129 
diagnosis of NAR might actually be classified as having Local allergic rhinitis 130 
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(LAR) because they have nasal symptoms after Nasal allergen provocation test 131 
(NAPT) with a common aeroallergen (24, 37), and local production of sIgE was 132 
detected in these patients. LAR is a localized nasal allergic response in the 133 
absence of systemic atopy characterized by local production of specific IgE 134 
(sIgE) antibodies, a TH2 pattern of mucosal cell infiltration during natural 135 
exposure to aeroallergens, and a positive nasal allergen provocation test 136 
response with release of inflammatory mediators (tryptase and eosinophil 137 
cationic protein) (25).As a result, a new etiological classification of rhinitis has 138 
been proposed (Table 1-1)(25, 38).However, it remains a matter of debate 139 
whether local sensitization would be the primary event in any AR disease and 140 
can develop into systemic classical AR in the future (25). This requires 141 
appropriate prospective studies.  142 
Table1-1 Etiologic classification of rhinitis. 143 
1. Allergic rhinitis 
 Allergic rhinitis (with systemic atopy) 
i. Classical classification 
1. Time of exposure to aeroallergen or aeroallergens: perennial, seasonal, and 
occupational 
ii. ARIA classification(32) 
1. Duration of symptoms: persistent and intermittent 
2. Severity of symptoms: mild, moderate, and severe 
 Local allergic rhinitis (without systemic atopy) 
i. Classical classification 
1. Time of exposure to aeroallergen or aeroallergens: perennial, seasonal, and 
occupational 
ii. ARIA classification(32) 
1. Duration of symptoms: persistent and intermittent 
2. Severity of symptoms: mild, moderate, and severe 
2. Nonallergic rhinitis 
 Infectious  
 Occupational (irritant) 












1.2.1.3 Eczema 146 
Eczema is a chronic inflammatory pruritic skin disease that affects a large 147 
number of children and adults in industrialized countries (39). It often begins in 148 
early infancy and follows a course of remissions and exacerbations(40), thus is 149 
considered to be one of the first manifestations in the atopic march. 50% of 150 
those with eczema during the first 2 years of life will develop asthma 151 
subsequently (41). The severity of eczema, including early sensitization to food, 152 
increases the risk of asthma and allergic rhinitis(40, 42).Infants typically 153 
present with erythematous papules and vesicles on the cheeks, forehead, or 154 
scalp, which are intensely pruritic(39).Scoring Atopic Dermatitis (SCORAD) 155 
(43) has been used to classify AD into 3 main severity forms: mild (<15), 156 
moderate (>15 and <40) and severe (>40).  157 
 158 
Eczema has been subtyped as allergic (formerly extrinsic) and nonallergic 159 
(formerly intrinsic), representing approximately 80% and 20% of adult patients, 160 
respectively (44).The term topic eczema is used when the underlying 161 
inflammation is dominated by an IgE-antibody associated reaction, determined 162 
based on an IgE-antibody determination or skin test. Otherwise it should be 163 
termed non-atopic eczema(21). 164 
 165 
1.2.2 The allergic march 166 
A pattern of progression through different allergic disorders in early childhood 167 
has been termed the ‘allergic march’, with eczema and food allergy dominating 168 
in early childhood, while asthma and rhinitis are more common later (45). 169 





Figure1-2 Incidences of different types of allergic diseases by age.(22) 173 
 174 
Evidence for the allergic march from eczema to allergic rhinitis and asthma are 175 
raised from longitudinal studies. Rhodes et al. (46, 47)followed 100 infants with 176 
at least one allergic parentup to 22years in the United Kingdom. The prevalence 177 
of eczema peaked at 1 year of agein 20% of children,but later declined to 178 
approximately 5% at 22 years of age. However, the prevalence of allergic 179 
rhinitis slowly increased over time, from 3% to 15%. The prevalence of parents 180 
reporting wheezing increased from 5% at the age of 1 year to 40% at 22 years of 181 
age. Moreover, sensitization to allergen tested by skin prick test increased over 182 
time to a peak of 36% at 22 years of life. The Tucson Children’s Respiratory 183 
Study found that eczema during the first 2 years of life was an independent risk 184 
factor for persistent wheezing up to 6 years of life, and was associated with 185 
inactive and chronic asthma but not with newly diagnosed asthma at 22 years 186 
old(30, 48).  187 
 188 
The putative mechanism of the allergic march is that the allergen exposure 189 
through the epidermis can initiate systemic allergy and predispose individuals 190 
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to allergic rhinitis, and asthma in the airways(45, 49). Epithelial barrier defects 191 
derived from loss-of-function mutations in the filaggrin gene have been 192 
identified as a strong predisposing factor for eczema and secondarily, to the 193 
development of asthma(50). Thymic stromal lymphopoietin (TSLP), 194 
apro-inflammatory factor derived from epithelial cells have also elicited 195 
considerable interest, asit has been shown to stimulate mast cells to produce 196 
TH2 cytokines(51).  197 
 198 
1.2.3 Fetal and early origin of allergic diseases 199 
The “development origins of health and disease” paradigm maintains that 200 
nutritional or other environmental stimuli during critical periods of growth and 201 
development have the potential to permanently “program” the structure and/or 202 
function of cell populations, emerging organ systems, or homeostatic pathways 203 
(52). Since Barker’s findings that exposures in utero could have lifelong 204 
influenceon cardiovascular diseases and othertraits (53), there has been 205 
considerable interest in the role of early life events plays in health and diseases.  206 
 207 
Early life origins of asthma have been recognized in birth cohort 208 
studies.Children who have a diagnosis of asthma have often started wheezing 209 
during infancy. Indeed early age of onset is a recognized risk factor for 210 
persistence of asthma(48, 54). The ALSPAC study which includes 6265 211 
children found thatof the children who have asthma at 7 years of age, about 40% 212 
have started wheezing during the first two years of life(28).Other longitudinal 213 
birth cohortshave shown strong association between lung function(55) and 214 
airway responsiveness(56) measured soon after birth and asthma later in 215 
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childhood. Furthermore, cohorts followed from childhood to adult life (57)have 216 
demonstrated that lung function changes associated with asthma become 217 
established in early childhood and then track to adulthood. Theseresultslead to 218 
the hypothesis that pulmonary developmental changes associated with asthma 219 
in childhood and even adulthood are already established at birth or shortlyafter 220 
that (3).On the other hand, fetal exposure to environmental factors such as 221 
maternal smoking, diet have been reported to be linked to the development of 222 
the fetal immune system(58),decreased lung function(59), and risk of 223 
developing asthma and wheezing in the offspring(60, 61). These evidences 224 
strengthen the hypothesis the fetus is not immunologically naive and 225 
intrauterine exposures can act directly to invoke immunological sensitization 226 
leading to postnatal airway inflammation. 227 
 228 
1.3 Polyunsaturated fatty acid (PUFA) 229 
1.3.1 Definition and nomenclature 230 
There are three kinds of fatty acid: saturated (SFA), monounsaturated (MUFA, 231 
possessing one carbon-carbon double bond), or polyunsaturated (PUFA, 232 
possessing two or more carbon-carbon double bond).  233 
 234 
The standard numbering system for fatty acids gives the number of carbon 235 
atoms, the number of double bonds (after a colon), and the position of the first 236 
double bond (after the letter n) counting from the end of the carbon chain 237 
opposite the carboxyl group. For example, linoleic acid (LA) is denominated as 238 
18:2n-6, because it has a total of 18 carbon atoms in the chain, with 2 double 239 
bonds, and the first double bond is on the 6
th
 carbon position from the methyl. In 240 
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addition, fatty acids are often expressed by their abbreviations. The fatty acids 241 
relevant to the current thesis are listed as follows: 242 
 Linoleic acid (LA; 18:2n−6) 243 
 Arachidonic acid (AA; 20:4n−6) 244 
 α-Linolenic acid (ALA; 18:3n−3) 245 
 Eicosapentaenoic acid (EPA; 20:5n−3) 246 
 Docosahexaenoic acid (DHA; 22:6n−3) 247 
 248 
1.3.2 Categories and biosynthesis of PUFAs 249 
The number, position,and configuration of the double bonds of PUFAs also 250 
largely determine their physicaland biologic properties. Biologically relevant 251 
families of PUFAs are the n–6 and the n–3 fatty acids. In the n-6 PUFA family, 252 
LA is the simplest member and as the precursor of n-6 family PUFAs, it is 253 
capable of being metabolized to longer-chain, more unsaturated n-6 PUFAs. LA 254 
is first converted to γ-linolenic acid (18:3 n–6) by Δ6-desaturase, and 255 
thenγ-linolenic acid can be elongated (by elongase) to dihomo-γ-linolenic acid 256 
(20:3 n–6). Dihomo-γ-linolenic acid canbe desaturated further by 257 
Δ5-desaturase, yielding AA. Similarly, ALA is the simplest members of n-3 258 
family PUFAs and can be synthesized to a sequence of longer chain n-3 fatty 259 
acids, including EPA and DHA. (Figure 1-3) During this process, n-3 and n-6 260 
PUFAs are competing for the same set of enzymes, such as δ-6 desaturase. 261 
Although supplemental ALA raises EPA and DPA status in the blood, ALA or 262 
EPA dietary supplements have little effect on blood DHA levels(62). This 263 
result demonstrates that the rate of conversion from ALA to DHA is very low 264 




Figure 1-3The biosynthesis of n−6 and n−3 polyunsaturated fatty acids. LA 267 
and ALA can be synthesized to more unsaturated PUFAs, during which 268 
process they are competing for the same set of enzymes.EPA and DHA, the 269 
most biologically relevant n–3 fattyacids, are highlighted in red.(63) 270 
 271 
 272 
1.3.3 Requirements and changing in intakes for PUFAs 273 
LA and ALA cannot be synthesized in mammals and human, as mammals lack 274 
enzymes to insert thedouble bond in the n–6 or n–3 position.Therefore they are 275 
defined as essential fatty acids to human. The lack of LA and ALA, as well as 276 
some of their elongatedand more unsaturated products, leads to a syndrome of 277 
deficiency (64, 65).This syndrome of deficiency is usually characterized by 278 
desquamativerashes and hyperkeratoticdermatoses in humans. Current 279 
estimates of the minimum requirementsfor n–6 and n–3 fatty acids in adults are 280 
1.0% and 0.2% of daily energy intake,respectively. (66)An expert consultation 281 
of FAO and WHO recommended that for adult males and 282 
non-pregnant/non-lactating adult females the acceptable macronutrient 283 
distribution range (IMDR) of DHA plus EPA should be0.25 to 2.0 g per day. 284 
For adult pregnant and lactating females, the minimum intake for optimal 285 
adult health and fetal and infant development is 0.3 g/d EPA+DHA, of which 286 
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at least 0.2 g/d should be DHA. There is insufficient evidence to set a specific 287 
minimum intake of either EPA or DHA alone; both should be consumed(66). 288 
 289 
LA is found in significant quantities in many vegetable oils, including corn, 290 
sunflower, and soybean oils, and in products made from such oils, such as 291 
margarines. AA is found in meat and offal and intakes are estimated at 50 to 500 292 
mg/day. EPA, DPA, and DHA are found in fish, especially so-called “oily” fish 293 
(tuna, salmon, mackerel, herring, and sardine). One oily fish meal can provide 294 
between 1.5 and 3.5 g of these long-chain n−3 PUFAs. Fish oils supplements 295 
available in the commercial market contain 30% long-chain n−3 PUFAs of the 296 
fatty acids in the capsule. Thus, consumption of a typical 1-g fish oil capsule per 297 
day can provide about 300 mg of these fatty acids. In the absence of oily fish or 298 
fish oil consumption, intake of long-chain n−3 PUFAs is likely to be <100 299 
mg/day, although foods fortified with these fatty acids are now available in 300 
many countries (15). In the United States, intake of n-3 fatty acids EPA and 301 
DHA is only 0.1–0.2 g/d (67), which is below the recommendation of 0.2g/d 302 




 century, the amount of linoleic acidin western diet has increased 305 
remarkably, with the change being most marked since the early 1960s. The 306 
availability of linoleic acid (LA) increased from 2.79% to 7.21% of energy from 307 
1909 to 1999 in the United States(68). These changes are in large part due to a 308 
significant increase in the use of margarine and vegetable oils, which contain 309 
large amount of LA. Although from 1909 to 1999, the availability of n-3 PUFA 310 
ALA increased 85% from 0.39% of energy to 0.72% of energy, there were no 311 
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remarkable changes in the availability of long-chain n-3 PUFAs EPA, DPA and 312 
DHA (68). As a result, the ratio of n-6 to n-3 fatty acids is around 9.8:1 at the 313 
end of 20
th
 century (67). This biased intake that favors n-6 PUFAs intake has 314 
been linked to the increased prevalence of a variety of diseases such as 315 
cardiovascular diseases (63)and allergic diseases(69).  316 
 317 
1.3.4 Biomarkers of PUFAs 318 
Accurate assessment of PUFA intake is essential to examine the associations 319 
between PUFAs in diet and disease risk in epidemiological research. However, 320 
relative intakes of individual PUFAs in the diet are difficult to estimate 321 
accurately from dietary assessment methods such as food frequency 322 
questionnaires food recall and food diary. This is in part because that 323 
respondents often under-report consumption, especially in obese population 324 
(70). Moreover, respondents would consciously or sub-consciously alter their 325 
usual diet, during the recording period. Interviewer bias and respondent burden 326 
also add to the imprecise measurement. Instead, using plasma fatty acids 327 
concentrations as a biomarker for dietary intake can complement the drawbacks 328 
dietary assessment methods, and have the potential to be used more 329 
quantitatively (71). It seems reasonable to expect that the best markers of 330 
dietary intake exist for the fatty acids that cannot be endogenously synthesized. 331 
These include the n-3 PUFAs (ALA from plant sources and long-chain n-3 fatty 332 
acids from marine sources), the n-6 polyunsaturated fatty acids (mostly from 333 
vegetable oils).  334 
 335 
Adipose tissue, plasma lipid fractions (such as plasma total phospholipids and 336 
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phosphorylcholine), and erythrocyte total phospholipids are the three types of 337 
human sample that are often used as biomarkers of PUFAs. The fatty acid 338 
composition of adipose tissue has been considered a gold standard for the 339 
representation of dietary fatty acids, due to the slow turnover time in weight 340 
stable individuals. The t1/2 of adipose tissue lipids were estimated to be between 341 
6 and 9 months using stable isotope methodology (72). Significant positive 342 
correlations between the relative intake of dietary PUFA and the relative content 343 
of adipose tissue n-6 and /or n-3 or total PUFA have been noted (71). Plasma 344 
lipid fractions can reflect only recent, that is the preceding few weeks, rather 345 
than long-term intake. Within days after altered composition of dietary fatty 346 
acids, the fatty acid composition of plasma lipid fractions change accordingly 347 
(73). Traditionally, fatty acids measured in erythrocytes were thought to 348 
represent fatty acid intake for several months, because erythrocytes have a life 349 
span of approximately 120 days. However, it has been reported that the fatty 350 
acid composition of erythrocyte PL reflects changes in dietary fatty acid intake 351 
within 24 h with an increase of LA (73) and this could only be explained by the 352 
exchange and transfer of fatty acids from plasma to erythrocytes. In this case, 353 
fatty acids measured in erythrocytes are representing a period of fatty acid 354 
intake as short as that in plasma lipid fractions.  355 
 356 
1.4 Mechanisms linking PUFA and allergy 357 
1.4.1 Mechanisms of allergy 358 
The immunological mechanism associated with allergy is the biased expression 359 
of T-lymphocyte and cell-mediated responses to common allergens towards 360 
T-helper-2 (Th-2) lymphocyte activity. Th-2 lymphocytes give rise to peptide 361 
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regulatory factors named cytokines. The Th-2 cytokinesinitiate the production 362 
of IgE, the primary allergy-promoting antibody, and activate inflammatory cells 363 
such as eosinophils, which are commonly associated with allergic inflammation. 364 
TheseTh-2 cytokines include interleukins (IL)-4, IL-5, IL-9 and IL-13. The 365 
counter-regulatory pathways include those generated by a normal immune 366 
response to infection dominated by the T-helper-1 (Th-1) lymphocytes. 367 
Th-1lymphocytes generate the cytokines interferon-gamma (IFN-γ) and IL-2. 368 
Another pathway involves a group of T-lymphocyte regulators which have an 369 
influence on both Th-1 and Th-2 activity either by cell-cell contact or by the 370 
generation of IL-10 and transforming growth factor (TGF)-β. Based on this 371 
mechanism it becomes clear that either overexpression of Th-2 activity or a 372 
failure of control by Th-1 or T-regulatory function will result in a higher 373 
probability of the development of allergy and allergic inflammation. The pattern 374 
of response of T-lymphocytes is dictated by the nature of the signaling from 375 
antigen-presenting cells (APCs). They in turn are affected by the nature of the 376 
antigen exposure. APCs generate IL-12, -15, -18 and -23 which predominantly 377 
stimulate Th-1 responses, whereas IL-10 from regulatory T-cells inhibits IL-12 378 
and therefore favors Th-2 activity. 379 
 380 
1.4.2 n-6 fatty acidsand allergic inflammation 381 
It has been suggested that there is a causal relationship between the increased 382 
intake of the n−6 PUFA LA over the latter part of the twentieth century and 383 
allergic disease (5). The key link between PUFAs and allergy lies in the 384 
eicosanoids generated from AA. AA in the inflammatory cell membrane 385 
phospholipids is the major precursor of for eicosanoid synthesis. (Figure 1-4) 386 
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Eicosanoids, which include prostaglandins (PGs), thromboxanes (TXs), 387 
leukotrienes (LTs) and other oxidized derivatives, are generated from AA by the 388 
action of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes within 389 
seconds to minutes of acute challenge of immune system. PGs and LTs are are 390 
widely appreciated for their pro-inflammatoryactivities(74, 75). For example, 391 
PGD2, which is produced mainly by mast cells and activated macrophages, is a 392 
potent bronchoconstrictor, promotes vascular permeability, and activates 393 
eosinophils and a Th2-type response. LTB4 is chemotactic for leukocytes, 394 
increases vascular permeability, induces the release of lysosomal enzymes and 395 
reactive oxygen species by neutrophils and of inflammatory cytokines (e.g., 396 
TNF-α) by macrophages, and promotes IgE production by B cells (15). The 397 
eicosanoids frequently have opposing effects (76).For example, although PGE2 398 
is well known for its pro-inflammatory property to inhibits the production of 399 
Th1-type cytokines and primes naïve T cells to produce IL-4 and IL-5, and 400 
promote the production of IgE(8, 74), it has also been found to have 401 
anti-inflammatory properties by promoting the formation of lipoxins, which is 402 
involved in the resolution of inflammation(69, 77). Thus, the overall 403 
physiologic (or pathophysiologic) outcome will depend on the nature of cell 404 
types present and the nature, timing and duration of the stimulus.Table 1-2 405 





Figure 1-4 Generalized pathway for the conversion of arachidonic acid to 409 
eicosanoids. COX, cyclooxygenase; HETE, hydroxyeicosatetraenoic acid; 410 
HPETE, hydroperoxyeicosatetraenoic acid; LOX, lipoxygenase; LT, 411 
leukotriene; PG, prostaglandin; TX, thromboxane.(69) 412 
 413 




Increases vascular permeability 
Increases vasodilatation 
Causes pain 
Enhances pain caused by other agents 
Increases production of IL-6 
 Anti-inflammatory 
Inhibits production of TNF and IL-1 
Inhibits 5-LOX (decreases 4-series LT production) 
Induces 15-LOX (increases lipoxin production) 
LTB4 
 Pro-inflammatory 
Increases vascular permeability 
Enhances local blood flow 
Chemotactic agent for leukocytes 
Induces release of lysosomal enzymes 
Induces release of reactive oxygen species by granulocytes 
Increases production of TNF, IL-1, and IL-6 
 415 
1.4.3 n-3 fatty acids and allergic inflammation 416 
N-3 PUFAs are potentially potent anti-inflammatory agents.This property of 417 
n-3 fatty acids were first postulated in the study of Greenland Eskimos (Inuits), 418 
whose diet was composed mainly of seal and whale and was extremely rich in 419 
marine n–3 fatty acids. A lower frequency of bronchial asthma, together with 420 
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other chronic diseases such as myocardial infarction was reported in Inuits, as 421 
compared with Danish controls (78).  422 
 423 
n−3 PUFAs, such as EPA and DHA act to counter the effect of n−6 PUFAs by 424 
competing for the same desaturase enzymes used to produce AA, and partly 425 
replacing AA in inflammatory cell membrane in a dose-response 426 
pattern(7).Because less substrate of AA is available for eicosanoids 427 
production,n-3 PUFAs can decrease the pro-inflammatory eicosanoids 428 
produced by inflammatory cells, such as PGE2 (79, 80), LTB4(81, 82), and 429 
5-hydroxyeicosatetraenoic acid (81, 82).On the other hand, EPAin 430 
inflammatory cells can also be metabolized into eicosanoids, such as LTB5, 431 
LTE5, and 5-hydroxyeicosapentaenoic acid(81, 82). (Figure 1-5) However, 432 
theseeicosanoids are in general much less potent local mediators than the 433 
corresponding n–6 fatty acid derivatives(69).For example, LTB5 is 10- to 434 
100-fold less potent as a neutrophil chemotactic agent than LTB4 (83). 435 
 436 
Figure 1-5 Generalized pathway for the conversion of eicosapentaenoic 437 
acid to eicosanoids.COX, cyclooxygenase; HEPE, hydroxyeicosapentaenoic 438 
acid;HPEPE, hydroperoxyeicosapentaenoic acid; LOX, lipoxygenase; LT, 439 




Recent research based on lipidomics and informaticsidentified a new family of 442 
dual anti-inflammatory and pro-resolution lipid mediators termed resolvins, 443 
which are derived from long-chain n-3 PUFAs. (77)They are so-named asthey 444 
proved to be potent regulators of resolution. The two chemically unique 445 
structural forms of resolvins, E-series and D-series are derived from EPA and 446 
DHA, respectively.The biosynthesis pathways of resolvins are showed in 447 
Figure 1-6. For example, EPA can be converted to 448 
18R-hydroperoxyeicosapentaenoic acid (18R-HPEPE) and rapidly 449 
transformed by activated human neutrophil 5‑lipoxygenase to Resolvin E1and 450 
E2. E‑series member resolvin E1 reduces inflammation and blocks human 451 
neutrophil transendothelial migration, thereby displaying potent 452 
anti-inflammatory actions.(84) 453 
 454 
DHA in resolving exudates is also converted to another molecule belonging to 455 
a new family of mediators named protectins.Protectin D1 blocks T‑cell 456 
migration in vivo, reduces TNF and interferon‑γ secretion and promotes T‑457 




Figure 1-6 Biosynthesis of resolvins and protectins from DHA and 460 
EPA.COX-2 denotes cyclooxygenase-2, cPLA2 cytosolic phospholipase A2, 461 
DHA docosahexaenoic acid, DiHDHAdihydroxy-docosahexaenoic acid, 462 
DiHp-ETE dihydroperoxy-eicosatetraenoic acid, EPA eicosapentaenoic acid, 463 
HETE hydroxy-eicosatetraenoic acid, 464 
HpDHAhydroperoxy-docosahexaenoicacid, 465 
HpEPEhydroperoxy-eicosapentaenoic acid, HPETE 466 
hydroperoxy-eicosatetraenoic acid, 5-LOX 5-lipoxygenase, 12-LOX 467 
12-lipoxygenase,14-LOX 14-lipoxygenase, 15-LOX 15-lipoxygenase, LTA4 468 
leukotriene A4, LXA4 lipoxin A4, LXB4 lipoxin B4, NPD1 neuroprotectin 469 
D1,and RV resolvin.(63) 470 
 471 
Other possible mechanisms of anti-inflammatory property of n-3 fatty acids 472 
might include reducing the capacity of Atigen Presenting Cells to present 473 
antigen to T cells, reducing T cell proliferation, influencing T regulatory cells 474 
(11). 475 
 476 
1.5 Literature review 477 
1.5.1 Cohorts of maternal PUFA status and offspring allergy 478 
Cohorts examining the relationship between maternal PUFAs status and 479 
offspring allergic outcomes have reached mixed results. (Table 1-3) The large 480 
ALSPAC cohort (19) found no relation between maternal red cell PUFAs and 481 
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wheezing and eczema before 4 years of age, and a small study by Yu and 482 
Bjorksten(20) found no association between maternal serum PUFAs and 483 
offspring atopic outcomes to 6 years of age. The SWS study (17)reported a 484 
modest protective effect of DHA, EPA and total n-3 PUFAs against non-atopic 485 
persistent wheezing up to 6 years of age, but not on other phenotypes of 486 
wheezing.Furthermore, the authors accepted that the chance of false positive 487 
finding cannot be excluded, as numbers of associations were tested. The 488 
KOALA Birth Cohort (18)unexpectedly reported a protective effect of AA 489 
against eczema in the first 7 months of life, and the ratio of n-6 to n-3 PUFAs 490 
against eczema in 6-7 years children. This is against the widely held notion 491 
that excessive AA and a high ratio of n-6 to n-3 PUFAs might increase the risk 492 
of allergic disease. (5, 69)  493 
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Table1-3Summaries of studies of maternal fatty acid status and allergic 494 
















Wheezing at 0 to 6 mo and 30 to 42 mo 
(n=1191); Eczema at 18 to 30 
mo(n=1238) 
Confounding: child’s sex, gestational 
age at birth, and birth weight, mother’s 
age, education level, housing tenure, 
parity, ethnicity, smoking in 
pregnancy, maternal atopic disease, 
child’s head circumference at birth, 
child’s crown to heel length at birth, 
mother’s body mass index, 
breast-feeding in first 6 months, and 
day care use in first 6 months. 
No significant result was found 
between maternal PUFA status 
and offspring transient 
wheezing, later-onset 









Wheeze, asthma, allergic 
rhinoconjunctivitis, eczema, atopic 
dermatitis, allergic sensitization, and 
high total IgE until the age of 6–7 
years (n=1275) 
Confounding: recruitment group, age 
of the mother, maternal ethnicity, 
maternal education level, maternal 
smoking during pregnancy, parental 
history of atopy and/or asthma, 
presence of older siblings, term of 
gestation, season of birth, gender, birth 
weight, mode of delivery, child 
exposure to environmental tobacco 
smoke, breastfeeding, child day care, 
and pets at home 
High ratio of maternal n-6 vs. 
n-3 LCPs was associated with a 
lower risk of eczema in the 
child (P for trend 0.012).  
More specifically, a decreased 
risk of eczema in the first 7 
months of life with increasing 
AA levels (P for trend 0.013) 
was reported.  
No associations were found 
between maternal fatty acids 
and offspring airway-related 
atopic manifestations, 





Airway inflammation; wheezing at 6, 
12, 24, and 36 mo and 6 years 
(transient, persistent, late-onset 
wheezing); SPT, fractional exhaled 
nitric oxide (FENO) measurement, 
and spirometry at 6 years. (n=865) 
Confounding: maternal asthma and 
rhinitis, parity, paternal asthma, 
maternal smoking in pregnancy, 
child’s sex, and maternal educational 
attainment, maternal smoking during 
pregnancy, and dogs/cats in the home 
during the child’s infancy.  
Higher maternal EPA, DHA, 
and total n-3 fatty acids were 
associated with reduced risk of 
nonatopic persistent/late 
wheezing (RR=0.57, 0.67 and 
0.69, resp. P = 0.01, 0.015, and 
0.021, resp.).A higher ratio of 
linoleic acid to its unsaturated 
metabolic products was 
associated with reduced risk of 
skin sensitisation (RR 0.82, P = 
0.013). 
  496 
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1.5.2 RCTs of maternal fish oil supplementation and offspring allergy 497 
SixRCTs were identified studying the effect of maternal fish oil 498 
supplementation during pregnancy onallergic outcomes in the 499 
offspring.Krauss-Etschmann et al. (86) reported that higher levels of DHA and 500 
EPA in both maternal andcord blood in group fish oil supplementation. 501 
Dunstan et al. (12)showed a higher DHA and EPA status in cord blood 502 
erythrocytes. These results demonstrated the effect of fish oil supplementation 503 
on elevating maternal and neonatal n-3 PUFA status. These studies also 504 
showed immunology changes towards a balanced Th1/Th2 response, such as 505 
lower cord blood plasma IL-13, more IL-5 responsive colony forming units, 506 
lowerIL-10 in response to cat allergen(12, 87-91)higher TGF-β mRNA, lower 507 
IL-4, IL-13 and CCR4 mRNA(86)in cord blood. These immunologiceffects of 508 
fish oil supplementation might have effect on allergic sensitization,and in turn 509 
on the development of allergic diseases in theoffspring.Dunstan et al. (12) 510 
reported a lower risk of a positive SPT to egg in fish oil group. Clinical 511 
outcomes of allergic diseases such as less severity of eczema (12), lower 512 
prevalence of food allergy and IgE associated eczema (14), asthma, allergic 513 
asthma, allergic diseases (13) were reported in the fish oil supplementation 514 
group. However, a recent study in Australia did not report any protective effect 515 
of fish oil supplementation on allergic sensitization or IgE associated allergic 516 
diseases (92).  517 
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Table 1-4Summaries of studies of maternal fish oil supplementation during 518 
pregnancy and allergic outcomes in infants and children. 519 
Reference  Study design Outcome measures 
 
Findings 



















SPT at age 1 year  
 
 
Clinical symptoms of allergic diseases 
(asthma, wheeze, food allergy,atopic 
dermatitis) at 1 year 
 
In cord blood: Plasma cytokine(Th2: IL-4, 
IL-5,IL-13, TNF-α; Th1: IFN-γ,IL-12,Treg: 
IL-10; Th17: IL-6,) 
 
APC function (HLA-DRexpression and 
cytokineresponses) 
 
Mononuclear cell cytokineresponses to 
allergens andmitogen (IL-5, IL-10, 
IL-13,IFN-γ) 
 




CD34+ cell expression ofcytokine (IL-5Rα, 
IL-3Rα) orchemokine(CXCR4, CCR3) 
receptors. 
 
Eosinophil/Basophil colonyforming units 
 
Leukotriene production bystimulated 
neutrophils 
 
In breast milk (3 days 
postpartum):Immunomodulatoryfactors - 
sCD14, IgA,cytokines (IL-5, IL-6, 
IL-10,TNF-α and IFN-γ) 
FO associated with: 
Lower risk of a positive 
SPT to egg (OR 0.34, 95% 
CI 0.11–1.02; p=0.055) 
Less severity in infants 
with atopic dermatitis (OR 
0.09, 95% CI 0.01–0.94; 
p=0.045) 














A higher percentage of 




More IL-5 responsive 
colonyforming units 
(p<0.003) 

















4 groups:  

















In maternal and cord blood at birth: 
Th1/Th2 related molecules: mRNAexpression 














In cord blood: 
Lymphocyte subsets 
Maternal FO was 
associatedwith: 
Higher TGF-β mRNA 
inmaternal and cord blood 
(both p<0.001) 
Lower IFN-γ and IL-1 
mRNAin maternal blood 
(all p<0.001) 
Lower IL-4, IL-13 and 
CCR4mRNA in cordblood 
(both p<0.001) 
Lower proportions of NK 
cellsand CCR3+ CD8+ 
T-cells incord blood 
(p<0.001and p<0.04, 
respectively) 






Clinical examinations ofinfants: 
Skin prick testing to cow’smilk, egg, and wheat 
at 6 and12 months of age 
 
Maternal FO was 
associated with: 
Lower prevalence of 
















From week 25 of 
pregnancy until 
end of lactation 
(3-4 months of 
breastfeeding) 
Plasma specific IgE to egg/milk/wheat at 3 
and12 months age 
 
IgE associated eczema and foodallergy at 3, 6, 
and 12 monthsof age 
 
 
In maternal wholeblood: 
Production of eicosanoids(PGE2, LTB4), 
cytokines(IFN-γ, IL-5, IL-6, TNF, IL-8,IL-10) 
and chemokines(CCL2, CCL3) by 






Lower prevalence of 
IgEassociatedeczema (8% 
vs. 




secretiondecreased in 64% 
of the 
FOsupplementedmothers 
andincreased in 77% of 
those in thecontrol group 
(p=0.002). Thedecreased 
PGE2 productionwas more 
pronounced amongnon 


































Allergic asthma,  
 
 
Asthma ofmixed type, atopic dermatitisor 
allergic rhinitis  
 
 
Allergic asthma, atopic dermatitis or allergic 
rhinitis 
 
data takenfrom the National patientregistry in 
Denmark 




Lower risk of asthma 
(OR=0.37,95% CI 
0.15–0.92, p=0.03) 
Lower risk of allergic 
asthma(OR=0.13, 95% CI 
0.03–0.60, p=0.01) 
Lower risk of asthma of 




Lower risk of allergic 
asthma,atopic dermatitis or 
allergicrhinitis (OR=0.31, 

































No significant differences 
were found 
 
  520 
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1.6 Study hypothesis and aims of study 521 
Hypothesis: Increased pro-inflammatory n-6 PUFA status and reduced 522 
anti-inflammatory n-3 PUFA status in pregnant women are associated with 523 
increased risk of childhood allergic diseases.  524 
 525 
Aim of the study: to examine the association of maternal PUFA status measured 526 
in plasma samples (percentage of total n-3 PUFAs, total n-6 PUFAs, n-6 to n-3 527 
PUFA ratio, and the specific n-6 and n-3 PUFAs)with clinical outcomes of 528 
potential allergic diseases (rhinitis, eczema, and wheezing), results from skin 529 
prick testing (SPT) and allergic diseases (SPT plus clinical outcomes) in 18 530 
months old children.  531 
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Chapter 2. METHODS 532 
2.1 Participants 533 
Participants were mother-child pairs in the Growing Up in Singapore Towards 534 
Healthy Outcomes (GUSTO) birth cohort. A detailed study profile has been 535 
described elsewhere(94, 95). In brief, the GUSTO study is designed to 536 
investigate the role of early life exposures in the development of metabolic and 537 
other diseases. Between June 2009 and September 2010, 1162 pregnant women 538 
aged 18 years and above were recruited in the main GUSTO. The study was 539 
granted ethical approval by the Institutional Review Board of the KK Women’s 540 
and Children’s Hospital (KKH) and National University Hospital (NUH). 541 
Informed written consent was obtained from each participant. 542 
 543 
Detailed interviews of maternal characteristics, including demographics, 544 
lifestyle, diet and health, were conducted at a recruitment clinic visit and again 545 
at 26–28 weeks of gestation. Infant characteristics, such as fetal anthropometry 546 
and health outcomes, were collected through examination at home at 3 weeks, 3 547 
months and every 3 months thereafter until 15 months of age. At the age of 18 548 
months, the mothers and infants were invited to the study clinic for detailed 549 
clinical assessment including allergic sensitization (skin prick testing). 550 
 551 
2.2 Maternal plasma polyunsaturated fatty acid (PUFA) 552 
Blood was taken into heparinized tubes at 26-28 weeks of gestation. Plasma was 553 
prepared and stored at -80°C until analysis. Plasma lipids were extracted with 554 
chloroform/methanol (2:1 vol/vol). Phosphatidylcholine (PC), which 555 
contributes about 75% of plasma phospholipid, was isolated by solid phase 556 
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extraction. Then, fatty acid methyl esters (FAMEs) were generated from PC 557 
after reaction with methanol containing 2% (vol/vol) sulphuric acid. FAMEs 558 
were extracted into hexane and separated by gas chromatography(Series 6890, 559 
Hewlett Packard, BPX 70column SGE Europe Ltd.). FAMEs were identified by 560 
comparison with retention times of standards run previously and they were 561 
quantified using ChemStation software(Agilent Technologies). Data was 562 
expressed as percentage contribution to the total plasma PC fatty acid pool. For 563 
all fatty acids within plasma PC, within-assay CV is < 3% and between assay 564 
CV is < 6%. In this study, we focused on percentage of total n-3 PUFA, total n-6 565 
PUFA, and n-6 to n-3 fatty acid ratio. Additionally, we examined the specific 566 
PUFAs, specificallyALA, EPA, docosapentaenoic acid (DPA; 22:5n−3), DHA, 567 
EPA+DHA, LA, and AA. 568 
 569 
2.3 Allergy outcome measurements 570 
2.3.1 Allergy sensitization – skin prick testing (SPT) 571 
Allergic sensitization was assessed by standardized SPT to common inhalant 572 
and food allergens. Standardized SPT was conducted by trained doctors during 573 
the clinic visit at 18 months of age using 3 food allergens (cow’s milk, peanut, 574 
and egg) and 3 house dust mites (Dermatophagoidespteronyssinus, 575 
Dermatophagoidesfarinae, Blomiatropicalis). Histamine and saline were used 576 
as positive and negative controls, respectively. Wheal size ≥3 mm was 577 
classified as positive. SPT was considered valid only if the positive wheal was 578 
≥3 mm, and the negative control exhibited no wheal reaction. A positive SPT to 579 




2.3.2 Early childhood rhinitis, eczema and wheezing 582 
Information on clinical outcomes of potential allergic diseases(eczema, rhinitis 583 
and wheezing) was collected serially at 7 time points: 3 weeks, 3 months and 584 
every 3 months thereafter till 18 months of age. Trained interviewers 585 
administered standardized questionnaires adapted from the International Study 586 
of Asthma and Allergies Questionnaire (ISAAC)(97) to the mother or main 587 
caregiver. Rhinitis was defined as parents’ positive response to the question: “At 588 
any time, has your child had running nose, blocked or congested nose, snoring 589 
or noisy breathing during sleep or when awake that has lasted for 2 or more 590 
weeks duration?” Doctor-diagnosed eczema was based on a positive answer to 591 
the question: “Has your child ever been diagnosed with eczema?” Wheezing 592 
was defined as “noisy breathing with a high-pitch, whistling sound heard from 593 
the chest, not the mouth”. In order to decrease false positive reporting of 594 
wheezing, we additionally added another question in which nebulizer/inhaler 595 
usage by a doctor was assessed. Wheezing was diagnosed with positive 596 
responses to both questions: “Has your child ever wheezed?” and “Has your 597 
child been prescribed with nebulizer/inhaler treatment since the last visit?” 598 
After getting results from the questionnaires, phone calls were made to ask for 599 
further details. Presence of doctor diagnosed eczema, rhinitis, or wheezing was 600 
indicated by a positive response during any one of the 7 follow up 601 
questionnaires during the first 18 months of life. 602 
 603 
2.3.3 Allergic diseases 604 
Any allergic disease with positive SPT was defined as having any one of 605 





2.4 Statistical methods 609 
All statistics were performed by using the statistical software package IBM 610 
SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). Two sample t-test was 611 
used for comparing means of continuous variables and chi-square test was used 612 
for comparing the distribution of categorical variables.Binary logistic 613 
regression models were used to test the independent associations between the 614 
various allergic outcomes (i.e. SPT, rhinitis, eczema, wheezing and any allergic 615 
disease with positive SPT in the offspring) and individual maternal PUFAs. 616 
PUFAs of interest were first treated as continuous explanatory variables 617 
(continuous model), and then categorized into quartiles within the total cohort 618 
to test for a possible non-linear relationship and to examine dose-response 619 
(categorical model). 620 
 621 
In the models, we adjusted for maternal characteristics including maternal age, 622 
ethnicity, gravidity, education level, energy intake, and infant characteristics 623 
including gender, birth weight, gestational age, duration of breastfeeding, 624 
family history of allergic diseases, which includes allergic rhinitis, eczema and 625 
asthma in first degree relatives of the children(i.e. father, mother and/or sibling), 626 
exposure to environmental tobacco smoke, child day care attendance, and cat or 627 
dog at home during the period up to 18 months of age. Subgroup analysis was 628 
also performed in the group of children with no family history of allergic 629 





To control for type 1 error due to the performance of multiple analyses, an 633 
adjusted P value < 0.01 (p=0.05 divided by 5 allergy outcomes) was used to 634 
indicate statistical significance. Results are presented as adjusted odds ratios 635 
(OR) with corresponding 95% confidence intervals.  636 
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Chapter 3. RESULTS 637 
3.1 Maternal PUFA status and rates of allergy outcomes 638 
3.1.1Maternal PUFA status 639 
Of the 1162 women enrolled in the main GUSTO birth cohort, 998 mothers with 640 
singleton live births had blood samples available for measurement of plasma 641 
PCfatty acids. The median (range) percentages for total n-3 and n-6 PUFAs 642 
were 6.18% (2.22% - 13.97%) and 34.22% (10.77% - 51.29%), respectively. 643 
Median values with their 25th and 75th percentiles of the other fatty acids can 644 
be found in Table 3-1. Similar to previous findings, the predominant n-3 PUFA 645 
in maternal plasma was DHA, and the major n-6 PUFAs were LA and AA(19).  646 
 647 
Table 3-1 Fatty acid composition of maternal plasma PC measured at 26-28 648 
weeks of gestation. 649 
Fatty acid exposure* Median 25th and 75th percentiles 
Total n-3 PUFAs % 6.18 5.00, 7.49 
ALA % 0.19 0.10, 0.28 
EPA % 0.52 0.35, 0.82 
DPA % 0.55 0.46, 0.69 
DHA % 4.61 3.60, 5.63 
DHA+EPA % 5.24 4.14, 6.423 
Total n-6 PUFAs % 34.22 32.38, 36.17 
LA % 21.79 19.49, 24.00 
AA % 7.80 6.80, 8.87 
Total n-6:n-3 PUFAs 5.49 4.52, 6.94 
PUFA, polyunsaturated fatty acid; ALA, a-linolenic acid, 18:3n-3;EPA, 650 
eicosapentaenoic acid, 20:5n-3; DPA, docosapentenoic acid, 22:5n-3; 651 
DHA,docosahexaenoic acid, 22:6n-3; LA, linoleic acid, 18:2n-6; AA, 652 
arachidonicacid, 20:4n-6. 653 
N=998 654 
*
Fatty acids were expressed as percentage of total plasma fatty acids.  655 
34 
 
3.1.2 Rates of allergy outcomes 656 
After excluding those with multiple missing confounders, only 960 mothers 657 
were included in the final analyses. Sample sizes varied for the individual 658 
outcomes due to different response rates(Figure3-1). SPT at 18 months was 659 
performed in 728 children, among which 103 (14.1%) showed a positive result. 660 
Of 808 children who had data on parental reported rhinitis up to 18 months of 661 
life, 214 (26.5%) had rhinitis. Of 833 children with data on parental reported 662 
doctor diagnosed eczema up to 18 months of life, 147 (17.6%) were diagnosed 663 
with eczema.Of 859 children with data on wheezing symptoms (parent-reported 664 
and use of nebulizer or inhaler), 94 (10.9%) had wheezing. Of 657 children with 665 
data on SPTand the occurrence of any allergic disease, 62 (9.4%) showed a 666 
positive result. Characteristics of mothers who agreed to have SPT performed 667 
on their children (n=728) and those who did not (n=232) were broadly 668 
similar(Table 3-2), except that those who agreed tended to be slightly older, and 669 
were more likely to have more than one child. 670 
 671 
 672 
Figure3-1: Flow chart of the participantsin this study.  673 
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Table 3-2 Comparison of maternal characteristics of those with SPT data and 674 




With SPT  Without SPT 
P-value* 
 
Mean SD  Mean SD 
n 728  232  
Maternalcharacteristics   
 
 
Age (years) 30.9 5.2  29.6 4.9 <0.005 
Gravidity>1 (%) 60.6  48.5 <0.005 
Educationalstatus (%)    0.63 
Primary/Secondary 32.0  31.2  
Post-secondary 36.3  32.9  
University 33.5  35.9  
Ethnicity (%)    0.75 
Chinese 54.3  56.7  
Malay 27.1  24.7  
Indian 18.6  18.6  
Totalenergyintake (KJ) 7891 2410  7698 2540 0.30 
Totaln-3PUFAs† 6.4 1.9  6.2 1.8 0.17 
Total n-6PUFAs† 34.2 3.3  34.1 3.7 0.79 






Gestationalage (weeks) 38.6 1.4  38.6 1.5 0.94 
Male gender (%) 50.8  54.1 0.41 
Monthsofbreastfeeding (%)    0.23 
None 7.3  9.1  
<4 43.7  40.3  
≥4 41.3  32.0  
Unknown 7.7  18.6  
Birthweight (g) 3116 440  3056 471 0.07 
Family history of allergic diseases (%)    0.66 
No 57.3  13.9  
1 parent 29.1  8.2  
2 parents 8.4  2.2  
Sibling only 5.2  0.4  
Unknown 0  75.3  
Environmental smoking duringinfancy (%)    0.24 
No 51.1  32.5  
Yes 32.1  26.0  
Unknown 16.8  41.6  
Childcare attendance during infancy (%)    0.87 
No 75.7  51.9  
Yes 7.3  5.2  
Unknown 17.0  42.9  
Cat/dogathome during infancy (%)    0.82 
No 74.3  51.9  
Yes 8.7  5.6  
Unknown 17.0  42.4  
Everrhinitis (%) 26.6  26.0 0.49 
Evereczema (%) 17.1  20.3 0.22 
Ever wheeze (%) 10.2  14.6 0.08 
SPT, Skin prick testing; SD, standard deviation. 676 
1
Values reflect the mean and standard deviation for continuous variables or 677 
percentages (%) for categorical variables, unless otherwise specified. 678 
2
Fatty acids were expressed as percentage of total plasma fatty acids. 679 
3
P-values obtained by 2-sample T-test for continuous variables and chi-square 680 
tests for categorical variables; P values ≤ 0.05 is significant  681 
36 
 
3.2 Population characteristics 682 
Table 3-3and Table 3-4 show the main characteristics of the study population 683 
and bivariate associations with the various clinical allergic outcomes. There 684 
was a higher tendency for infants with eczema, wheeze and any allergic disease 685 
with positive SPT to be breastfed for longer than 4 months. Prevalence of 686 
rhinitis and eczema was highest in infants with both parents having allergic 687 
disease compared to those with one parent having allergic disease and was 688 
lowest in those with no family history of allergic disease. There was a higher 689 
prevalence of rhinitis and wheeze seen in infants who attended childcare during 690 
infancy. Additionally, the prevalence of eczema was higher in children of 691 
first-time pregnancies and those whose mothers had higher educational 692 
qualifications, while the prevalence of wheeze was higher is male infants and in 693 
infants with shorter gestational age.For all of the clinical allergic outcomes, 694 
Malay infants have the highest prevalence, followed by Chinese infants with the 695 
lowest prevalence in the Indian infants. This coincided with the prevalence of 696 
infants having family history of allergic diseases among the ethnic groups. In 697 
addition, Chinese mothers tended to have the highest plasma PC n-3 PUFA 698 
levels, lowest plasma PC n-6 PUFA levels and n-6:n-3 PUFA ratio, while Malay 699 
mothers had the highest n-6:n-3 PUFA ratio (Table 3-5). 700 
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SPT any allergic diseases with SPT* ever rhinitis  ever eczema ever wheeze 
 
Unit no yes  
P-value† 
no yes  
P-value† 
No yes  
P-value† 
no yes  
P-value† 
no yes  
P-value† 
  
n=625 n=103 n=595 n=62 n=594 n=214 n=686 n=147 n=765 n=94 
Maternal characteristics 
               
Age  years 30.8(5.2) 31.5(5.3) 0.21 31(5.2) 32(5.2) 0.15 31.0(5.1) 30.6(5.6) 0.41 30.8(5.1) 31.3(5.2) 0.25 30.8(5.1) 30.1(5.3) 0.22 
Gravidity >1 No 248(86.4) 39(13.6) 0.75 239(91.9) 21(8.1) 0.41 249(72.8) 93(27.2) 0.70 278(79.2) 73(20.8) 0.04 328(91.1) 32(8.9) 0.12 
 










Educational status Primary/Secondary 189(85.9) 31(14.1) 0.68 176(91.2) 17(8.8) 0.75 170(73.3) 62(26.7) 0.99 211(86.8) 32(13.2) 0.01 226(90.8) 23(9.2) 0.40 
 





















Ethnicity Chinese 340(86.1) 55(13.9) 0.05 333(92) 29(8) 0.01 348(76) 110(24) <0.005 375(80.6) 90(19.4) 0.02 432(89.6) 50(10.4) <0.005 
 





















Total energy intake KJ 7845(2414) 8171(2380) 0.20 7928 (2469) 8247(2117) 0.33 7858(2469) 8021(2381) 0.40 7849(2481) 8176(2222) 0.14 7853(2423) 7858(2481) 0.99 
Total n-3PUFAs‡ % 6.4(1.9) 6.5(1.8) 0.50 6.4(1.9) 6.8(1.8) 0.21 6.4(1.9) 6.6(1.8) 0.15 6.4(1.9) 6.5(1.9) 0.50 6.4(1.9) 6.6(2.0) 0.22 
Total n-6PUFAs‡ % 34.3(3.3) 33.8(3.5) 0.18 34.2(3.4) 34(2.8) 0.66 34.2(3.5) 34.1(2.9) 0.87 34.1(3.5) 34.1(2.9) 0.99 34.3(3.4) 33.4(2.9) 0.02 
n-6:n-3PUFAs ratio  
 
5.9(2.0) 5.6(1.9) 0.28 5.8(2.0) 5.5(1.9) 0.20 5.9(2.1) 5.6(1.6) 0.01 5.8(2.0) 5.7(1.9) 0.57 5.9(2.0) 5.5(1.8) 0.11 
SD, standard deviation; SPT, Skin prick testing. 702 
Values reflect the mean (standard deviation) for continuous variables orabsolute numbers (percentage) for categorical variables, unless otherwise 703 
specified. 704 
1
Any allergic diseases with SPT was defined as having any one of the clinical outcomes with a positive SPT. 705 
2
P-valuesobtainedby 2 sample t-testforcontinuousvariablesandchi-squaretestsforcategoricalvariables; P ≤ 0.05 is significant. 706 
3
Fatty acids were expressed as percentage of total plasma fatty acids.  707 
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SPT any allergic diseases with SPT* ever rhinitis  ever eczema ever wheeze 
 
Unit no yes  
P-value† 
no yes  
P-value† 
No yes  
P-value† 
no yes  
P-value† 
no yes  
P-value† 
  
n=625 n=103 n=595 n=62 n=594 n=214 n=686 n=147 n=765 n=94 
Infant characteristics 
               
Gestational age weeks 38.6(1.39) 38.8(1.41) 0.41 38.7(1.35) 38.6(1.56) 0.51 38.7(1.38) 38.6(1.21) 0.30 38.7(1.32) 38.7(1.76) 0.91 38.8(1.3) 38.3(1.66) <0.005 
Gender Male 310(83.8) 60(16.2) 0.11 297(89.5) 35(10.5) 0.35 296(71.2) 120(28.8) 0.13  346(80.7) 83(19.3) 0.20  389(87) 58(13) 0.05 
 












none 47(88.7) 6(11.3) 0.46 46(95.8) 2(4.2) 0.06 52(77.6) 15(22.4) 0.70 57(86.4) 9(13.6) 0.02 67(95.7) 3(4.3) 0.06 
































Birth weight  g 3107(444) 3176(413) 0.14 3118(434) 3157(414) 0.66 3117(447) 3135(417) 0.61 3100(433) 3159(468) 0.14 3125(446) 3061(407) 0.19 
Family history of  
allergic diseases 
No 361(86.6) 56(13.4) 0.75 334(92.5) 27(7.5) 0.27 318(80.1) 79(19.9) <0.005 370(87.1) 55(12.9) <0.005 399(91.3) 38(8.7) 0.11 
1 parent 178(84.0) 34(16.0)  173(87.4) 25(12.6)  143(66.8) 71(33.2)  169(75.8) 54(24.2)  198(88.8) 25(11.2)  
 2 parents 52(85.2) 9(14.8)  50(87.7) 7(12.3)  35(55.6) 28(44.0)  47(74.6) 16(25.4)  53(82.8) 11(17.2)  
 Sibling only 34(89.5) 4(10.5)  32(91.4) 3(8.6)  25(67.6) 12(32.4)  31(81.6) 7(18.4)  32(82.1) 7(17.9)  




No  312(83.9) 60(16.1) 0.23 309(89.6) 36(10.4) 0.36 307(75.1) 102(24.9) 0.54 339(81.7) 76(18.3) 0.82 391(90.1) 43(9.9) 0.35 






















No  472(85.7) 79(14.3) 0.96 460(91.1) 45(8.9) 0.68 453(76.1) 142(23.9) <0.005 516(82.8) 107(17.2) 0.18 586(90.6) 61(9.4) <0.005  




















Cat/dog at home during 
infancy 
No  464(85.8) 77(14.2) 0.99 456(91.4) 43(8.6) 0.34 439(74.3) 152(25.7) 0.67 506(82.5) 107(17.5) 0.33 566(89) 70(11) 0.91  























SD, standard deviation; SPT, Skin prick testing;  709 
Values reflect the mean (standard deviation) for continuous variables or absolute numbers (percentage) for categorical variables, unless 710 
otherwise specified.; 711 
1
Any allergic diseases with SPT was defined as having any one of the clinical outcomes with a positive SPT.; 712 
2
P-values obtained by2 sample t-test for continuous variables and chi-square tests for categorical variables; P ≤ 0.05 is significant. 713 
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Table3-5Comparison of maternal plasma PC PUFAs and family history of 714 




Chinese  Malay  Indian 
P-value* 
 
Mean SD  Mean SD 
 
Mean SD 
n 527  254  179  
Total n-3PUFAs† 6.7 1.9  6.0 1.7  6.0 1.8 <0.005 
Total n-6PUFAs† 33.8 3.4  34.1 3.2  35.3 3.5 <0.005 
n-6:n-3PUFAs ratio  5.5 1.8  6.1 1.9  6.5 2.4 <0.005 
Family history of allergic diseases (%)      0.18 
No 46.2  44.9  51.4  
1 parent 25.7  26.4  16.2  
2 parents 6.1  7.1  8.9  
Sibling only 4.0  3.5  5.0  
Unknown 18.1  18.1  18.4  
SD, standard deviation. 716 
Values reflect the mean and standard deviation for continuous variables or 717 
percentages (%) for categorical variables, unless otherwise specified. 718 
1
P-values obtained by one-way analysis of variance (ANOVA) for continuous 719 
variables and chi-square tests for categorical variables; P values ≤ 0.05 is 720 
significant. 721 
2
Fatty acids were expressed as percentage of total plasma fatty acids.  722 
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3.3 Association between maternal PUFA status and offspring allergy 723 
outcomes 724 
In bivariate analyses using quartiles of PUFAs(Table 3-6), weak trends ofhigher 725 
maternal plasma PC n-3 PUFAs being associated with any allergic diseases with 726 
positive SPT in infants (P=0.07),lower maternal plasma PC n-6 PUFAs being 727 
associated with wheeze in infants (P=0.06) and lower maternal n-6:n-3 PUFA 728 
ratio being associated with wheeze and any allergic diseases with positive SPT 729 
in infants (P=0.06;P=0.07) were observed. These trends were not as clearly 730 
observed in the group of infants without family history of allergic diseases 731 
(P >0.1 for all)(Tables 3-7).  732 
42 
 
Table 3-6Infant allergy outcomesaccordingtoquartilesofmaternaltotalplasma 733 
PC n-3 PUFA, n-6 PUFA status and n-6:n-3 PUFA ratio. 734 
 
Q1  Q2  Q3  Q4 P-value
1 
Totaln-3 PUFAs2 2.2-5.0  5.1-6.1  6.2-7.5  7.6-14.0  
n 240  240  240  240  







SPT (%) 13.2  13.1  11.7  18.3 0.22 
Everrhinitis (%) 20.7  28.6  30.2  25.9 0.25 
Evereczema (%) 17.6  18.5  14.5  19.9 0.79 
Everwheeze (%) 10.2  10.0  11.3  12.2 0.43 
Any allergicdiseases with SPT3 (%) 6.6  9.4  7.8  13.3 0.07 
 Q1  Q2  Q3  Q4 P-value* 
Totaln-6 PUFAs2 10.8-32.3  32.4-34.2  34.3-36.1  36.2-51.3  
n 240  240  240  240  







SPT (%) 17.5  9.9  13.2  16.0 0.92 
Everrhinitis (%) 27.1  24.9  29.6  24.5 0.45 
Evereczema (%) 15.7  18.3  17.6  18.9 0.45 
Everwheeze (%) 13.6  11.6  11.0  7.6 0.06 
Any allergicdiseases with SPT3 (%) 9.6  7.9  11.7  8.7 0.93 
 Q1  Q2  Q3  Q4 P-value* 
n-6:n-3 PUFAs ratio 1.9-4.5  4.6-5.4  5.5-6.9  7.0-16.6  
n 240  240  240  240  







SPT (%) 18.8  11.5  13.4  12.5 0.13 
Everrhinitis (%) 26.6  27.9  32.0  18.9 0.21 
Evereczema (%) 20.6  11.4  19.7  18.8 0.88 
Everwheeze (%) 14.3  10.6  10.0  8.5 0.06 
Any allergicdiseases with SPT3(%) 12.6  8.8  9.4  6.4 0.07 
Q,quartile; SD, standard deviation; SPT, Skin prick testing. 735 







Any allergicdiseases with SPT was defined as having any one of the clinical 740 
outcomes with a positive SPT  741 
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Table 3-7Infant allergy outcomesaccordingtoquartilesofmaternaltotalplasma 742 
PC n-3 PUFA, n-6 PUFA status and n-6:n-3 PUFA ratioin the group without 743 
family history of allergic diseases. 744 
 
Q1  Q2  Q3  Q4 P-value
1 
Total n-3 PUFAs2 2.2-5.0  5.1-6.1  6.2-7.5  7.6-14.0  
n 115  115  115  115  







SPT (%) 11.8  12.0  12.4  17.5 0.25 
Ever rhinitis (%) 11.6  23.1  26.0  19.4 0.17 
Ever eczema (%) 9.2  13.6  13.1  16.2 0.17 
Ever wheeze (%) 8.7  6.2  9.2  10.7 0.43 
Any allergic diseases with SPT3 (%) 4.8  8.5  5.6  10.6 0.24 
 
Q1  Q2  Q3  Q4 P-value* 
Total n-6 PUFAs2 10.8-32.3  32.4-34.2  34.3-36.1  36.2-51.3 
 
n 115  115  115  115 
 







SPT (%) 18.4  9.3  13.1  12.9 0.39 
Ever rhinitis (%) 18.6  17.8  23.9  20.4 0.54 
Ever eczema (%) 11.4  14.5  13.3  13.2 0.78 
Ever wheeze (%) 10.9  9.6  9.3  4.7 0.12 
Any allergic diseases with SPT3 (%) 10.0  5.5  9.4  5.2 0.38 
 
Q1  Q2  Q3  Q4 P-value* 
n-6:n-3 PUFAs ratio2 1.9-4.4  4.5-5.4  5.5-6.9  7.0-15.8 
 
n 115  115  115  115 
 







SPT (%) 16.7  13.0  10.6  13.5 0.43 
Ever rhinitis (%) 21.2  22.0  22.9  14.3 0.28 
Ever eczema (%) 16.4  12.8  13.1  10.0 0.20 
Ever wheeze (%) 10.8  9.8  7.3  6.7 0.22 
Any allergic diseases with SPT3 (%) 8.5  9.6  4.7  6.8 0.42 
Q, quartile; SD, standard deviation; SPT, Skin prick testing. 745 
Values reflect the percentages (%) for categorical variables, unless otherwise 746 
specified. 747 
1
P-values obtained by chi-square tests for categorical variables. 748 
2
Fatty acids were expressed as percentage of total plasma fatty acids. 749 
3
Any allergic diseases with SPT was defined as having any one of the clinical 750 
outcomes plus a positive SPT.  751 
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Upon adjustment for potential confounders (Table 3-8), no statistically 752 
significant linear relationships between the individual maternal PUFAs as 753 
continuous variables and any of the various allergic outcomes were observed. 754 
From quartile analyses, a weak positive trend between maternal plasma PC n-3 755 
PUFAs and any allergic diseases with positive SPT in infants persisted.The 756 
odds ratio of any allergic diseases with positive SPT was highest (OR=2.09) in 757 
the highest quartile of n-3 PUFAs when compared to the lowest quartile 758 
(reference), although this was not statistically significant. This was also 759 
observed in the group of infants without family history of allergic diseases 760 
(Table 3-9).No clear associations were observed with maternal plasma PC total 761 
n-6 PUFA statusand the risk of having any allergic disease with SPT up to 18 762 
months of age. Correspondingly, a negative trend was observed between 763 
maternal plasma PC n-6: n-3 PUFA ratio and the risk of having any allergic 764 
disease with SPT up to 18 months of age in the whole cohort only, although this 765 
did not reach statistical significance. 766 
 767 
While the odd ratios for wheezing in infants appear to be lower with increasing 768 
quartiles of maternal plasma PC n-6 PUFAs and n-6:n-3 PUFA ratios, and the 769 
odds ratio for ever eczema in infants appear to be higher with increasing 770 
quartiles of maternal plasma PC n-6 PUFAs in both the whole cohort and in the 771 
group of infants without family history of allergic diseases, these associations 772 
were not statistically significant. The odd ratios for ever rhinitis in infants 773 
appear to be higher with increasing quartiles of maternal plasma PC n-3 PUFAs 774 
and n-6:n-3 PUFA ratios, but only up to the 3
rd
 quartile, in both the whole cohort 775 
and in the group of infants without family history of allergic diseases(Table 3-8 776 
and Table 3-9). However, these associations were not statistically significant.  777 
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Table 3-8. Association between maternal plasma PC PUFA status at 26-28 778 
weeks of pregnancy and early childhood allergic diseases 779 
Quartiles of 
plasma fatty acids 
 
Adjusted OR (95% CI)
1
 




diseases with SPT2 Ever rhinitis Ever eczema   Ever wheeze 
Range(wt%
) n=72834 n=65734 n=80834 n=83334 n=85934 
Total n-3 PUFAs 
      Continuous model 
 
1.03 (0.91,1.16) 1.08 (0.93,1.25) 1.07 (0.98,1.17) 0.99 (0.89,1.09) 1.06 (0.93,1.20) 
Categorical model       
1 ≤5.00 1(reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 5.01-6.18 0.91(0.48,1.72) 1.38 (0.58,3.28) 1.56 (0.96,2.54) 1.02 (0.60,1.74) 0.90 (0.45,1.78) 
3 6.19-7.49 0.83(0.43,1.58) 1.10 (0.45,2.71) 1.67 (1.03,2.70) 0.67 (0.38,1.18) 1.09 (0.56,2.13) 
4 ≥7.50 1.41(0.77,2.58) 2.09 (0.91,4.78) 1.34 (0.81,2.21) 0.93 (0.55,1.60) 1.12 (0.57,2.2) 
Total n-6 PUFAs 
      
Continuous model 
 
0.97 (0.90,1.03) 1.00 (0.92,1.09) 1.01 (0.96,1.06) 1.03 (0.98,1.10) 0.94 (0.88,1.01) 
Categorical model       
1 ≤32.38 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 32.39-34.22 0.48 (0.25,0.90) 0.75 (0.34,1.68) 0.92 (0.58,1.46) 1.29 (0.76,2.20) 0.79 (0.43,1.46) 
3 34.23-36.17 0.71 (0.39,1.28) 1.26 (0.59,2.65) 1.17 (0.74,1.84) 1.37 (0.80,2.35) 0.76 (0.40,1.43) 
4 ≥36.18 0.98 (0.55,1.74) 1.02 (0.47,2.23) 1.00 (0.63,1.60) 1.56 (0.91,2.68) 0.67 (0.34,1.34) 
n-6:n-3 
PUFAsratio 
      Continuous model 
 
0.96 (0.85,1.08) 0.93 (0.79,1.09) 0.91 (0.83,1.00) 1.03 (0.93,1.14) 0.93 (0.82,1.07) 
Categorical model       
1 ≤4.52 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 4.53-5.49 0.60 (0.33,1.10) 0.70 (0.34,1.46) 1.11 (0.7,1.75) 0.55 (0.32,0.97) 0.70 (0.38,1.30) 
3 5.50-6.94 0.67 (0.37,1.21) 0.75 (0.36,1.56) 1.34 (0.85,2.11) 1.19 (0.72,1.97) 0.64 (0.34,1.23) 
4 ≥6.95 0.66 (0.36,1.22) 0.52 (0.23,1.21) 0.66 (0.40,1.10) 1.21 (0.71,2.06) 0.63 (0.32,1.25) 




Odds ratios (ORs) for the independent association between maternal total n-3, 781 
total n-6 PUFA status and n-6 to n-3 PUFAs ratio in plasma 782 
phosphatidylcholine at 26-28 weeks of pregnancy and various childhood 783 
allergic outcomes. Binary logistic regressions were performed using PUFAs as 784 
continuous variables (continuous model) and then as categorical variables 785 
(divided into quartiles in categorical model) respectively.  786 
2
Any allergic diseases with SPT was defined as having any one of the clinical 787 




Number of cases: SPT at 18 months of age 103/728, any allergic diseases 789 
with SPT 62/657, ever rhinitis 0 to 18 months of age 214/808, ever diagnosed 790 
eczema 147/833, and ever wheezing with nebulizer 94/859.  791 
4
Adjusted for maternal age, education level, energy intake, infant ethnicity, 792 
gender, gravidity, birth weight, gestational age, length of breastfeeding, family 793 
history of allergic diseases, exposure to environmental tobacco smoke, child 794 
day care attendance, cat/dog at home during infancy.  795 
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Table 3-9. Association between maternal plasma PC PUFA status at 26-28 796 
weeks of pregnancy and early childhood allergic diseases in the group with no 797 
family history of allergic diseases 798 
Quartiles of 
plasma fatty acids 
 
Adjusted OR (95% CI)
1
 




diseases with SPT2 Ever rhinitis Ever eczema   Ever wheeze 
Range(wt%) N=41834  N=36234 N=39834 N=42634  N=43834 
Total n-3 PUFAs 
      Continuous model 
 
1.02 (0.87,1.20) 1.07 (0.86,1.33) 1.08 (0.95,1.24) 1.07 (0.92,1.25) 1.04 (0.86,1.27) 
Categorical model       
1 ≤5.08 1(reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 5.09-6.21 0.94 (0.40,2.23) 1.49 (0.39,5.62) 2.54 (1.12,5.77) 1.40 (0.56,3.49) 0.64 (0.21,1.92) 
3 6.22-7.63 1.00 (0.41,2.40) 0.92 (0.22,3.92) 2.47 (1.07,5.68) 1.27 (0.50,3.21) 0.71 (0.25,2.05) 
4 ≥7.64 1.36 (0.59,3.14) 1.84 (0.50,6.84) 1.99 (0.85,4.67) 1.43 (0.58,3.54) 1.10 (0.40,3.05) 
Total n-6 PUFAs 
      Continuous model 
 
0.95 (0.87,1.04) 0.98 (0.86,1.11) 1.04 (0.96,1.12) 1.05 (0.96,1.14) 0.96 (0.86,1.08) 
Categorical model       
1 ≤32.34 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 32.35-34.32 0.43 (0.18,1.00) 0.50 (0.15,1.66) 0.99 (0.46,2.11) 1.39 (0.60,3.21) 0.69 (0.27,1.78) 
3 34.33-36.19 0.69 (0.32,1.51) 1.11 (0.38,3.26) 1.34 (0.64,2.81) 1.48 (0.63,3.48) 0.83 (0.32,2.15) 
4 ≥36.20 0.75 (0.34,1.67) 0.64 (0.19,2.16) 1.38 (0.66,2.89) 1.50 (0.63,3.57) 0.49 (0.16,1.58) 
n-6:n-3 PUFAs 
ratio 
      
Continuous model 
 
0.94 (0.80,1.11) 0.91 (0.71,1.16) 0.91 (0.79,1.04) 0.96 (0.81,1.12) 0.97 (0.79,1.20) 
Categorical model       
1 ≤4.45 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 4.46-5.48 0.90 (0.41,1.99) 1.38 (0.48,4.01) 1.02 (0.49,2.10) 0.90 (0.40,1.99) 0.70 (0.27,1.84) 
3 5.49-6.92 0.64 (0.28,1.50) 0.57 (0.16,2.11) 1.22 (0.60,2.47) 0.93 (0.42,2.05) 0.68 (0.24,1.89) 
4 ≥6.93 1.05 (0.46,2.41) 1.16 (0.34,3.92) 0.64 (0.29,1.42) 0.83 (0.34,2.04) 0.69 (0.23,2.05) 




Odds ratios (ORs) for the association between maternal total n-3and total n-6 800 
PUFA status and n-6 to n-3 PUFAs ratio in plasma phosphatidylcholine at 801 
26-28 weeks of pregnancy and various childhood allergic outcomes, 802 
respectively. Binary logistic regressions were performed using PUFAs as 803 
continuous variables  (continuous model) and then as categorical variables 804 
( divided into quartiles in categorical model) respectively. 805 
2
Any allergic diseases with SPT was defined as having any one of the clinical 806 




Number of cases: SPT at 18 months of age 56/418, any allergic diseases with 808 
SPT27/362, ever rhinitis 0 to 18 months of age 75/398, ever diagnosed eczema 809 
56/426, and ever wheezing with nebulizer 38/438.  810 
4
Adjusted for maternal age, education level, energy intake, infant ethnicity, 811 
gender, gravidity, birth weight, gestational age, length of 812 
breastfeeding,exposure to environmental tobacco smoke, child day care 813 
attendance, cat/dog at home during infancy.  814 
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When examining the individual PUFAs (ALA, EPA, DPA, DHA, EPA+DHA, 815 
LA, and AA), it appears that DPA and EPA were the key n-3 PUFAs driving the 816 
association with higher risk of any allergic diseases with positive SPT, while 817 
DHA was the key n-3 PUFA driving the association with higher risk of rhinitis. 818 
For the two n-6 PUFAs examined (LA, AA), there was no clear association with 819 
higher risk of wheeze and eczema (Table 3-10). Analyses were also conducted 820 
using PUFA concentrations, rather than percentages, with allergic outcomes and 821 
results were not different to those described above (data not shown). 822 
 823 
Table 3-10. Association between specific maternal plasma PC PUFAs at 26-28 824 
weeks of pregnancy and early childhood allergic diseases 825 
Quartiles of 









diseases with SPT† Ever rhinitis Ever eczema   Ever wheeze 
Range(wt%) N=728‡§  N=657‡§ N=808‡§ N=833‡§  N=859‡§ 
n-3 PUFAs 
      
ALA 
      
Continuous model 
 
0.85 (0.18,4.01) 0.79 (0.11,5.78) 0.47 (0.14,1.63) 1.26 (0.34,4.62) 0.59 (0.10,3.42) 
Categorical model       
1 ≤0.10 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 0.11-0.18 0.80 (0.43,1.49) 1.10 (0.49,2.47) 1.18 (0.74,1.89) 0.87 (0.50,1.51) 1.22 (0.61,2.44) 
3 0.19-0.27 0.92 (0.51,1.68) 1.34 (0.61,2.92) 0.95 (0.59,1.52) 1.07 (0.64,1.81) 1.77 (0.91,3.46) 
4 ≥0.28 0.85 (0.46,1.55) 0.99 (0.44,2.19) 0.86 (0.54,1.38) 0.87 (0.51,1.47) 1.12 (0.56,2.24) 
EPA 
      
Continuous model 
 
0.97 (0.66,1.44) 1.05 (0.66,1.68) 1.03 (0.78,1.36) 1.03 (0.74,1.41) 1.08 (0.75,1.57) 
Categorical model       
1 ≤0.35 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 0.36-0.51 1.12 (0.57,2.21) 1.07 (0.42,2.74) 1.09 (0.68,1.77) 1.14 (0.64,2.04) 1.07 (0.52,2.21) 
3 0.52-0.82 1.26 (0.65,2.47) 1.93 (0.80,4.67) 1.02 (0.63,1.66) 1.07 (0.60,1.89) 1.19 (0.60,2.36) 
4 ≥0.83 1.82 (0.94,3.50) 1.83 (0.76,4.45) 1.04 (0.64,1.69) 1.20 (0.68,2.13) 1.20 (0.60,2.39) 
DPA 
      
Continuous model 
 
1.44 (0.49,4.25) 2.99 (0.79,11.39) 1.10 (0.47,2.55) 1.79 (0.70,4.60) 1.21 (0.37,3.95) 
Categorical model       
1 ≤0.46 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 0.47-0.55 0.93 (0.48,1.80) 1.18 (0.48,2.90) 0.72 (0.45,1.17) 1.74 (0.97,3.11) 0.60 (0.31,1.17) 
3 0.56-0.69 1.20 (0.62,2.29) 1.38 (0.57,3.35) 0.80 (0.49,1.28) 1.62 (0.90,2.92) 0.64 (0.33,1.26) 
4 ≥0.70 1.46 (0.78,2.72) 2.05 (0.91,4.61) 1.03 (0.65,1.64) 1.54 (0.86,2.76) 0.68 (0.36,1.30) 
DHA 
      
Continuous model 
 
1.03 (0.89,1.20) 1.11 (0.92,1.35) 1.13 (1.00,1.27) 0.96 (0.84,1.09) 1.07 (0.91,1.27) 
Categorical model       
1 ≤3.60 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 3.16-4.59 0.90 (0.48,1.65) 0.92 (0.40,2.09) 1.53 (0.94,2.50) 1.02 (0.61,1.70) 0.95 (0.49,1.86) 
3 4.60-5.63 0.73 (0.38,1.40) 0.83 (0.35,1.98) 1.97 (1.22,3.21) 0.61 (0.35,1.07) 0.98 (0.49,1.96) 
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4 ≥5.64 1.24 (0.69,2.24) 1.51 (0.70,3.26) 1.42 (0.87,2.32) 0.80 (0.47,1.35) 1.15 (0.60,2.22) 
DHA+EPA 
      
Continuous model 
 
1.02 (0.90,1.16) 1.08 (0.92,1.27) 1.09 (0.99,1.21) 0.97 (0.87,1.09) 1.06 (0.93,1.22) 
Categorical model       
1 ≤4.14 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 4.15-5.21 0.83 (0.44,1.57) 1.06 (0.45,2.50) 1.71 (1.05,2.79) 1.20 (0.70,2.03) 1.25 (0.64,2.44) 
3 5.22-6.42 0.85 (0.45,1.61) 1.23 (0.52,2.91) 1.72 (1.05,2.80) 0.77 (0.44,1.34) 0.97 (0.48,1.95) 
4 ≥6.43 1.20 (0.66,2.19) 1.60 (0.71,3.61) 1.40 (0.85,2.31) 0.85 (0.49,1.47) 1.20 (0.61,2.36) 
n-6 PUFAs 
      
LA 
      
Continuous model 
 
0.97 (0.91,1.03) 1.00 (0.92,1.09) 1.00 (0.95,1.05) 1.02 (0.97,1.08) 0.95 (0.88,1.02) 
Categorical model       
1 ≤19.49 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 19.50-21.79 1.03 (0.57,1.86) 1.38 (0.64,2.97) 1.31 (0.83,2.07) 1.17 (0.68,2.01) 0.54 (0.28,1.05) 
3 21.80-24.00 0.70 (0.37,1.30) 0.70 (0.30,1.65) 0.91 (0.56,1.46) 1.09 (0.63,1.87) 0.89 (0.48,1.62) 
4 ≥24.01 0.95 (0.52,1.72) 1.18 (0.55,2.54) 1.07 (0.67,1.72) 1.41 (0.83,2.40) 0.62 (0.32,1.20) 
AA 
      
Continuous model 
0.99 (0.86,1.13) 1.01 (0.85,1.19) 1.04 (0.94,1.15) 0.94 (0.83,1.07) 0.99 (0.86,1.15) 
Categorical model       
1 ≤6.80 1 (reference） 1 (reference） 1 (reference） 1 (reference） 1 (reference） 
2 6.81-7.79 1.34 (0.74,2.42) 1.43 (0.68,3.04) 0.86 (0.54,1.36) 1.07 (0.64,1.78) 0.93 (0.50,1.73) 
3 7.80-8.87 1.16 (0.62,2.17) 1.52 (0.68,3.40) 1.18 (0.74,1.87) 1.40 (0.84,2.34) 0.83 (0.42,1.63) 
4 ≥8.88 1.22 (0.63,2.35) 1.09 (0.45,2.61) 0.98 (0.60,1.60) 0.66 (0.36,1.23) 1.06 (0.54,2.08) 
OR, odds ratio; SPT, skin prick testing.ALA, a-linolenic acid, 18:3n-3; EPA, 826 
eicosapentaenoic acid, 20:5n-3; DPA, docosapentaenoic acid, 22:5n-3; DHA, 827 





Odds ratios (ORs) for the association between maternal total n-3and total n-6 830 
PUFA status and n-6 to n-3 PUFAs ratio in plasma phosphatidylcholine at 831 
26-28 weeks of pregnancy and various childhood allergic outcomes, 832 
respectively. Binary logistic regressions were performed using PUFAs as 833 
continuous variables  (continuous model) and then as categorical variables 834 
( divided into quartiles in categorical model) respectively. 835 
†
Any allergic diseases with SPTwas defined as having any one of the clinical 836 




Number of cases: SPT at 18 months of age 103/728, any allergic diseases 838 
with SPT 62/657, ever rhinitis 0 to 18 months of age 214/808, ever diagnosed 839 
eczema 147/833, and ever wheezing with nebulizer 94/859.  840 
§
Adjusted for maternal age, education level, energy intake, infant ethnicity, 841 
gender, gravidity, birth weight, gestational age, length of breastfeeding, family 842 
history of allergic diseases, exposure to environmental tobacco smoke, child 843 
day care attendance, cat/dog at home during infancy.  844 
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Chapter 4. DISCUSSION 845 
In this Asian birth cohort study, we did not find any significant protective 846 
effects of higher percentages of n-3 PUFAs or lower percentages of n-6 PUFAs 847 
in maternalplasmaPCagainst offspring allergic diseases in early childhood. 848 
 849 
These results are in line with the large ALSPAC cohort(19)that showed no 850 
significant relation between maternal red cell PUFAs and offspring wheezing 851 
and eczema before 4 years of age, and a small study by Yu and 852 
Bjorksten(20)that found no significantassociation between maternal serum 853 
PUFAs and offspring asthma, eczema, allergic rhinoconjunctivitisand SPTupto 854 
6 years of ageamong 47 mother-child pairs.The levels of n-3 PUFAs in the 855 
above two studies appear to be lower compared to this study (DHA+EPA 856 
median level for ALSPACstudy =2.62%; meanlevel in Yuet al.’s study=2.72%). 857 
This most likely reflects the different fractions reported which have different 858 
PUFA contents.Despite lower levels of maternalplasma PC total n-3 859 
PUFAs(median=5.01%) than in the current study,the SWS study(17)reported a 860 
modest protective effect of DHA, EPA and total n-3 PUFAs against non-atopic 861 
persistent wheezing up to 6 years of age, but not on other phenotypes of 862 
wheezing. In contrast, we found a weak trend of higher total n-6 PUFAs and 863 
lower likelihood of ever wheeze in our cohort. A possible explanation for the 864 
difference in our results could be the specific wheezing patterns that SWS used, 865 
which were not captured in our study. Another possible explanation is the 866 
younger age of offspring in our study group, as respiratory allergy usually 867 
occurs at an older age (from preschool age)(28). Interestingly, the KOALA 868 
Birth Cohort(18)unexpectedly reported a protective effect of maternalAA 869 
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against eczema in the first 7 months of life, and ofthe ratio of n-6 to n-3 PUFAs 870 
against eczema in 6-7 yearold children. This is against the widely held notion 871 
that excessive AA and a high ratio of n-6 to n-3 PUFAs might increase the risk 872 
of allergic disease(5, 69). In contrast, we found a weak trend of increased total 873 
n-6 PUFAs and increased likelihood of ever eczema. 874 
 875 
The inconsistent results emerging from the above observational studies are in 876 
contrast to the results from some interventional studies using fish oil 877 
supplementation.Fish oil supplementation during late pregnancy appears to 878 
protect against developing a positive SPT, food allergy and IgE-associated 879 
eczema and asthma in the offspring(12-14). The EPA+DHA levels in plasma 880 
phospholipids achieved in the fish oil supplement groups of these randomized 881 
trials(86) were higher (mean= 8.02%) than the levels in our cohort 882 
(mean=5.37%) and in other cohorts (ALSPAC median in red blood cells, 883 
2.62%)(19). Therefore, it is possible that the protective effect of n-3 fatty acids 884 
can only be observed with the high intake achieved by supplementation, rather 885 
than the lower intakes consumed by the general population.  886 
 887 
Another possible explanation for the lack of association in our study is that 888 
children of age 18 months may be  too young for allergic evaluation, as many 889 
symptoms of wheezing, rhinitis and eczema are yet not associated with obvious 890 
allergy (i.e. positive SPT)(28). Further follow-up is necessary, as although the 891 
prevalence of allergic diseases increases with age, it has not been elucidated 892 
whether maternal PUFA status during pregnancy has a long-term effect and 893 




The present study has some methodological strengths. Recall bias of the allergic 896 
clinical outcomes was reduced by the repeated questionnaires with relatively 897 
short time-intervals and phone call confirmation after interviews, and data on 898 
confounding variables were collected prospectively.Blood samples were used 899 
to measure PC PUFA concentrations, which would be a more reliable nutrient 900 
biomarker than dietary recalls of PUFA intakes, which can be subjected to recall 901 
bias and under-reporting. 902 
 903 
Some limitations in the current study merit consideration. Firstly, maternal 904 
plasma PC PUFA levels in our analysis were based on a single measurement at 905 
26-28 weeks of pregnancy, which only reflects recent fatty acid intake in the 906 
proceeding few weeks, rather than long-term intake(71, 98-100). Therefore, it 907 
may not reflect levels of maternal PUFAs throughout the whole pregnancy. It 908 
has been previously shown that PUFA levels in plasma phospholipids do change 909 
throughout pregnancy(101). Secondly, we did not consider the influence of 910 
postnatal fatty acid exposure of the children, which also has been reported to be 911 
associated with childhood allergic diseases(102). Third, we could not rule out 912 
the possibility of misclassification as some of the exposure and outcome 913 
measurements (e.g. maternal allergy, infants’ allergic diseases) were based on 914 
self or parental reported information, rather than clinical diagnosis by a medical 915 
doctor or objective measures such as IgE analyses. Subjects who did not report 916 
a positive answer at any time point but had missing data at more than two time 917 
points were classified as “missing”, while those with missing data at only one or 918 
two time point were included as controls. It is acknowledged that this may lead 919 
to an overestimation of the prevalence of clinical outcomes.Moreover, the 920 
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information obtained by questionnaire did not assess in detail the severity of the 921 
outcomes and different phenotypes of clinical outcomes. Finally, as with any 922 
observational studies, we cannot rule out the possibility of residual confounding 923 
by unknown factors, even though we controlled for major known confounders.   924 
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Chapter 5. CONCLUSION 925 
Findings from this study provide no support for the hypothesis that the risk of 926 
early childhood allergic diseases is modified by variation in maternal exposure 927 
to n-3 and n-6 PUFAs during pregnancy in an Asian population. Further follow 928 
up of the children to an older age is highly recommended. Overall, results from 929 
observation studies examining the relationship between maternal PUFAs and 930 
offspring early allergic outcomes are inconclusive. Well-conducted and 931 
sufficiently-powered dietary or supplementation trials to examine 932 
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